What is Aplidin’s activity in myeloma?
Aplidin has potent anti-myeloma activity against patient myeloma cells, including those that are resistant to other myeloma agents. Aplidin clinical studies have shown additive or synergistic effects with other anti-myeloma drugs.
Final results of a small Phase II study in patients with relapsed/refractory myeloma (n=47) show activity of Aplidin in a heavily-pretreated patient population. The overall response rate (complete, partial, and minimal responses) was 13% with Aplidin alone. When dexamethasone was added (n=18), the overall response rate increased to 22%. Aplidin was well tolerated. Anemia and low platelet counts were the most frequent severe hematologic toxicities, and transient increases in liver enzymes and fatigue were the most common nonhematologic side effects.